ALLIANCES AND COLLABORATIONS (Sanofi) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended				3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended			3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2013 Avapro Avalide [Member]	Jun. 30, 2012 Avapro Avalide [Member]	Jun. 30, 2013 Avapro Avalide [Member]	Jun. 30, 2012 Avapro Avalide [Member]	Jun. 30, 2013 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Jun. 30, 2012 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Jun. 30, 2013 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Jun. 30, 2012 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Jun. 30, 2013 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Jun. 30, 2012 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Jun. 30, 2013 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Jun. 30, 2012 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2018 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Jun. 30, 2013 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2012 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Jun. 30, 2013 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Jun. 30, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Jun. 30, 2013 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Jun. 30, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]
Alliances and Collaborations Statement [Line Items]
Payment from Sanofi related to restructuring of the alliance agreement																			$ 200
Royalty revenue															56		107
Previously deferred profit recognized upon restructuring of an alliance agreement																								22
Controlling interest ownership percentage																				50.10%		50.10%		50.10%
Equity method investment ownership percentage																						49.90%		49.90%
Noncontrolling interest ownership percentage																				49.90%
Net Sales	4,048	4,443	7,879	9,694			56	117	102	324	33	30	51	68	100	858	237	2,758
Royalty expense																141	2	508
Equity in net income of affiliates	(50)	(53)	(86)	(110)																		(54)	(58)	(94)	(118)
Other (income)/expense	199	(51)	180	(235)											(4)	(47)	(14)	(61)
Noncontrolling interest - pre-tax															(1)	249	23	854
Distributions to Sanofi			(34)	(1,056)											(22)	(449)	(22)	(1,058)
Distributions to BMS																						21	62	52	129
Investment in affiliates																						51		51		9
Noncontrolling interest	2	(286)	2	(286)	15	(89)														(29)	(30)
Net sales																						128	319	177	638
Gross profit																						104	132	141	270
Net income																						$ 102	$ 120	$ 138	$ 242